Updates are available Correction dated 2022-03-16
Click to view Correction: https://doi.org/10.1038/s41409-022-01625-6
-
Authors
Jimenez Jimenez, Antonio M. https://orcid.org/0000-0003-2817-6836
De Lima, Marcos https://orcid.org/0000-0002-8568-4522
Komanduri, Krishna V.
Wang, Trent P. https://orcid.org/0000-0001-5685-7204
Zhang, Mei-Jie
Chen, Karen
Abdel-Azim, Hisham
Abid, Muhammad Bilal https://orcid.org/0000-0002-1128-0445
Aljurf, Mahmoud
Alkhateeb, Hassan
Assal, Amer https://orcid.org/0000-0003-4707-9265
Bacher, Ulrike
Baron, Frédéric https://orcid.org/0000-0002-2944-3812
Battiwalla, Minoo
Beitinjaneh, Amer
Bejanyan, Nelli https://orcid.org/0000-0003-0194-7338
Bhatt, Vijaya Raj https://orcid.org/0000-0003-2513-0533
Byrne, Michael
Cahn, Jean-Yves
Cairo, Mitchell https://orcid.org/0000-0002-2075-434X
Castillo, Paul https://orcid.org/0000-0002-2813-1729
Copelan, Edward
DeFilipp, Zachariah https://orcid.org/0000-0002-7994-8974
Perez, Miguel Angel Diaz
Elsawy, Mahmoud https://orcid.org/0000-0001-9872-2471
Gale, Robert Peter
George, Biju
Grunwald, Michael R. https://orcid.org/0000-0001-5407-9875
Hildebrandt, Gerhard C. https://orcid.org/0000-0003-0478-3340
Hogan, William J. https://orcid.org/0000-0002-5841-4105
Kanakry, Christopher G.
Kansagra, Ankit https://orcid.org/0000-0001-6901-0782
Kharfan-Dabaja, Mohamed A. https://orcid.org/0000-0001-7394-5185
Khera, Nandita
Krem, Maxwell M.
Lazaryan, Aleksandr https://orcid.org/0000-0001-9605-6436
Maakaron, Joseph https://orcid.org/0000-0002-1732-6694
Martino, Rodrigo
McGuirk, Joseph https://orcid.org/0000-0002-0539-4796
Michelis, Fotios V.
Milone, Giuseppe https://orcid.org/0000-0002-7840-4414
Mishra, Asmita https://orcid.org/0000-0003-3065-4294
Murthy, Hemant S.
Mussetti, Alberto
Nathan, Sunita https://orcid.org/0000-0001-7920-4265
Nishihori, Taiga https://orcid.org/0000-0002-2621-7924
Olsson, Richard F.
Palmisiano, Neil
Patel, Sagar https://orcid.org/0000-0001-9949-3615
Saad, Ayman
Seo, Sachiko https://orcid.org/0000-0002-4308-2152
Sharma, Akshay https://orcid.org/0000-0003-3281-2081
Solh, Melhem https://orcid.org/0000-0003-3766-5623
Verdonck, Leo F.
Wirk, Baldeep https://orcid.org/0000-0002-2804-2531
Yared, Jean A. https://orcid.org/0000-0002-5346-6299
Litzow, Mark https://orcid.org/0000-0002-9816-6302
Kebriaei, Partow https://orcid.org/0000-0002-8607-9404
Hourigan, Christopher S. https://orcid.org/0000-0002-6189-8067
Saber, Wael
Weisdorf, Daniel https://orcid.org/0000-0001-8078-8579
- License Information
-
More Information
Article History
Received: 13 May 2021
Revised: 31 July 2021
Accepted: 23 August 2021
First Online: 28 September 2021
Change Date: 16 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41409-022-01625-6
Competing interests
: AA reports grants and personal fees from Incyte Corporation, personal fees from Boston Biomedical, personal fees from Alpha Insights, outside the submitted work. NB reports personal fees from Magenta therapeutics, outside the submitted work. J-YC reports Advisory Boards with Agios, AbbVie, Otsuka, Race Oncology. VRB reports personal fees from Agios, grants and personal fees from Incyte, personal fees from Takeda, personal fees from Partner Therapeutics, personal fees from Omeros, grants and personal fees from Abbvie, grants from Jazz, grants from National Marrow Donor Program, other from Oncoceutics, personal fees from Partnership for health analytic research, LLC, grants and other from Pfizer, personal fees from CSL Behring, grants from Tolero Pharmaceuticals, personal fees from Rigel Pharmaceuticals, other from Novartis, personal fees from Genentech, outside the submitted work. MdL reports grants from Pfizer, grants from Celgene, personal fees from Kadmon, personal fees from Pfizer, personal fees from Incyte, personal fees from BMS, outside the submitted work. RPG is a consultant to BeiGene Ltd., Kite Pharma Inc., Fusion Pharma LLC, LaJolla NanoMedical Inc., Mingsight Parmaceuticals Inc., and CStone Pharmaceuticals; Medical Director, FFF Enterprises Inc.; Partner, AZCA Inc.; Board of Directors, RakFond Foundation for Cancer Research Support; Scientific Advisory Board, Antegene Biotech LLC and StemRad Ltd. MRG reports personal fees from Abbvie, personal fees from Agios, personal fees from Amgen, personal fees from Cardinal Health, personal fees from BMS/Celgene, personal fees from Daiichi Sankyo, personal fees and other from Incyte, personal fees from Merck, personal fees from Pfizer, personal fees from Premier, personal fees from Karius, other from Forma Therapeutics, other from Genentech/Roche, other from Janssen, personal fees from Astellas, personal fees from Trovagene, personal fees from Stemline, personal fees from Gilead, outside the submitted work. GCH reports other from Pfizer, other from Kite Pharma, other from Incyte, other from Jazz Pharmaceuticals, other from Alexion Pharmaceutical, other from Karyopharm, other from Pharmacyclics, other from Takeda, other from Jazz Pharmaceuticals, other from Kite Pharma, other from Incyte, other from Pfizer, other from Falk Foundation, other from Astellas Pharma, outside the submitted work. CSH reports other from Sellas, outside the submitted work. AK reports other from Takeda, other from Jansen, other from Pfizer, other from Celgene/BMS, other from Sanofi, other from Alynylam, other from GSK, other from Karyopharm, other from Oncopeptide, outside the submitted work. MAK-D reports other from Daiichi Sankyo, other from Pharmacyclics, outside the submitted work. JM reports grants and personal fees from AlloVir HCP, grants and personal fees from Juno Therapeutics, Inc, grants and personal fees from Gilead-Kite Pharmaceuticals, grants and other from Magenta Therapeutics, other from EcoR1 Cap, outside the submitted work. AM reports grants from Novartis, from null, outside the submitted work. AM reports grants from Gilead, personal fees from Novartis, Brystol-Myers Squibb, outside the submitted work. SP reports personal fees from Kite Pharma, outside the submitted work. RFO reports personal fees from AstraZeneca, outside the submitted work. AS reports personal fees from Magenta Therapeutics, personal fees from Incyte Pharmaceuticals, personal fees from CareDx, outside the submitted work. AS reports clinical trial salary support from Vertex Pharmaceuticals, CRISPR Therapeutics, Novartis paid to his institution, and personal consultancy fees from Spotlight Therapeutics, outside the submitted work. All other authors declare no potential competing interests.
